Syenza News — health technology assessment, market access and health economics
New Drug Launch Prices Stay High While Patients Wait for Access
New drug launch prices are still high. ICER’s 2026 Launch Price and Access Report finds the median net price for 2025 approvals was about $257,000, and only about one in three new prescriptions was filled within 30 days. #SyenzaNews #MarketAccess #HEOR
Recent Posts
CagriSema Weight Loss in Women: Menopause Stages in REDEFINE 1
Oct 21
Medicaid Provider Taxes Raise Private Insurance Premiums, ASPE Finds
Oct 21
Biomarker laboratory in Portugal opens at University of Porto
Oct 20
Emvistegrast in ulcerative colitis hits Phase 2 primary endpoint
Oct 20
Jemperli rectal cancer approval may let some patients skip standard treatment
Oct 20Syenza's Top Picks
Multiple Sclerosis Health Utilities Decline With Disability
Oct 9, 2026
BNT113 head and neck cancer trial misses first endpoint
Oct 14, 2026
Rapid-Acting Insulin Analogue Cost-Effectiveness in Type 1 Diabetes: What the Evidence Shows
Oct 14, 2026
Denosumab Ascend Biosimilar Wins EU Authorisation for Bone Complications
Oct 14, 2026
Health Security in Europe: Why Resilience Starts Before a Crisis
Oct 13, 2026
Health Investment Returns: What Berlin’s Funding the Future Panel Argued
Oct 13, 2026
Latest News
Clinical Practice
Adverse reaction reports in Portugal rise with GLP-1 use
Infarmed has logged 695 suspected adverse reactions to GLP-1 drugs in Portugal since 2024, most linked to Mounjaro.
Clinical Practice
Foundayo Oral GLP-1 Tablet Gets Positive EU Opinion
The EMA’s CHMP has backed Foundayo, a once-daily orforglipron tablet, for weight management and type 2 diabetes.
Clinical Practice Free account
EMA Draft Reflection Paper Sets Rules for Confirmatory Platform Trials
“EMA’s draft reflection paper sets out how confirmatory platform trials should handle controls, randomisation, blinding and multiplicity. Comments are due 31 January 2027. #SyenzaNews #MarketAccess #ClinicalTrials”
Clinical Practice
Reinforcement learning rTMS for depression treatment
Reinforcement learning rTMS for depression: a new npj Digital Medicine study tests protocol recommendations against clinician choices in 1,609 adults.
Clinical Guidelines And Protocols
AI operating room scheduling: LLM agent teams reach feasible plans
How can AI-powered scheduling transform operating room efficiency and deliver major cost savings?
Recent advancements are enabling hospitals to optimize resource allocation, reduce cancellations, and streamline workflows through intelligent automation.
Discover how this technology is reshaping surgical operations and improving financial outcomes.
#SyenzaNews #AIinHealthcare #HealthcareInnovation #ai #DigitalTransformation
Drug Pricing
Most favored nation drug pricing: why US patient groups push back
The National Health Council says importing foreign price controls through most favored nation pricing will not serve American patients.
Clinical Guidelines And Protocols Free account
FDA Rare Disease Framework Initiative Would Tailor Review to Small Populations
What steps is the FDA taking to accelerate rare disease treatments?
The FDA’s new Rare Disease Framework Initiative aims to streamline regulatory pathways, enhance collaboration with sponsors, and improve patient access to innovative therapies.
Explore how this could reshape drug development for underserved patient populations.
#SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #healthcarepolicy
Clinical Practice
Semaglutide for Opioid Use Disorder: $13.3M Trial Planned in Allegheny County
Researchers and Allegheny County plan a $13.3 million trial of weekly semaglutide to reduce opioid and alcohol use and justice involvement.
Artificial Intelligence And Machine Learning
AI guidance in clinical development: what industry is asking for
Regulators at the HMA-EMA AI group on 5 October 2026 outlined AI guidance in clinical development, with a concept paper and public consultation to follow.
Clinical Practice
Social prescribing in Portugal: pilots, gaps and the cost of time
Social prescribing is not yet part of Portugal’s national health system. Economists are asking whether it works, and who pays for it.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.
